Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia

Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5–35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Roilides, Emmanuel, Carlesse, Fabianne, Tawadrous, Margaret, Leister-Tebbe, Heidi, Conte, Umberto, Raber, Susan, Swanson, Robert, Yan, Jean L., Aram, Jalal A., Queiroz-Telles, Flavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Williams & Wilkins 2020
Materias:
Antimicrobial Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182240/
https://www.ncbi.nlm.nih.gov/pubmed/32032174
http://dx.doi.org/10.1097/INF.0000000000002568
Descripción
Sumario:Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5–35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients.

Ejemplares similares